Green Cross

Green Cross (006280 KS): Look Ahead for Key Milestones Amid Covid Vaccine Related Setback

Equity Bottom-Up
214 Views, 15 Jan 2022 23:01
EXECUTIVE SUMMARY
  • Green Cross (006280 KS) is currently waiting for marketing approval from the FDA for its immune globulin intravenous injection, which will mark its entry into the U.S. market.
  • The company will start commercializing its hemophilia A treatment, GreenGene F in China market this year. As a third-generation product, GreenGene is expected to gain substantial market share.
  • Green Cross shares remained subdued last year, as the company could not finalize a contract manufacturing deal for COVID-19 vaccine.
detail (4-minute read)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
logo
Logo
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Health CareEquity Bottom-UpThematic (Sector/Industry)

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare compa... 

Zoom:
NaN%
x